KDventures writes down Umecrine Cognition holding by SEK 226.4 million to zero

• KDventures announced October 30, 2026, a 100% write-down of its Umecrine Cognition holding from SEK 226.4 million to SEK 0.
• The adjustment will reduce net asset value by SEK 226.4 million, equivalent to approximately SEK 0.30 per share.
• The write-down follows golexanolone’s failure to demonstrate statistically significant cognitive improvement versus placebo or a fatigue benefit in its PBC trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.